Evidence map›Paper›PMID 29708182›Full record

ArticleNeurology. Clinical practice2018

Neurologist-patient communication about epilepsy in the United States, Spain, and Germany.

John M Stern, Fernando Cendes, Frank Gilliam, Patrick Kwan, Philippe Ryvlin, Joseph Sirven, Brien Smith, Aleksandra Adomas, Lauren Walter

Abstract read
In one paragraph

Article in Neurology. Clinical practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

John M SternDavid Geffen School of Medicine (JMS), University of California Los Angeles; University of Campinas (UNICAMP) and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) (FC), Campinas, São Paulo, Brazil; University of Kentucky Epilepsy Center (EpiC) (FG), Lexington; University of Melbourne (PK), Parkville, Australia; Centre Hospitalier Universitaire Vaudois (PR), Lausanne, Switzerland; Mayo Clinic (JS), Scottsdale, AZ; Spectrum Health Medical Group (BS), Grand Rapids, MI; MicroMass Communications, Inc. (AA), Cary, NC; and Verilogue, Inc. (LW), Horsham, PA.
Fernando CendesDavid Geffen School of Medicine (JMS), University of California Los Angeles; University of Campinas (UNICAMP) and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) (FC), Campinas, São Paulo, Brazil; University of Kentucky Epilepsy Center (EpiC) (FG), Lexington; University of Melbourne (PK), Parkville, Australia; Centre Hospitalier Universitaire Vaudois (PR), Lausanne, Switzerland; Mayo Clinic (JS), Scottsdale, AZ; Spectrum Health Medical Group (BS), Grand Rapids, MI; MicroMass Communications, Inc. (AA), Cary, NC; and Verilogue, Inc. (LW), Horsham, PA.
Frank GilliamDavid Geffen School of Medicine (JMS), University of California Los Angeles; University of Campinas (UNICAMP) and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) (FC), Campinas, São Paulo, Brazil; University of Kentucky Epilepsy Center (EpiC) (FG), Lexington; University of Melbourne (PK), Parkville, Australia; Centre Hospitalier Universitaire Vaudois (PR), Lausanne, Switzerland; Mayo Clinic (JS), Scottsdale, AZ; Spectrum Health Medical Group (BS), Grand Rapids, MI; MicroMass Communications, Inc. (AA), Cary, NC; and Verilogue, Inc. (LW), Horsham, PA.
Patrick KwanDavid Geffen School of Medicine (JMS), University of California Los Angeles; University of Campinas (UNICAMP) and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) (FC), Campinas, São Paulo, Brazil; University of Kentucky Epilepsy Center (EpiC) (FG), Lexington; University of Melbourne (PK), Parkville, Australia; Centre Hospitalier Universitaire Vaudois (PR), Lausanne, Switzerland; Mayo Clinic (JS), Scottsdale, AZ; Spectrum Health Medical Group (BS), Grand Rapids, MI; MicroMass Communications, Inc. (AA), Cary, NC; and Verilogue, Inc. (LW), Horsham, PA.
Philippe RyvlinDavid Geffen School of Medicine (JMS), University of California Los Angeles; University of Campinas (UNICAMP) and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) (FC), Campinas, São Paulo, Brazil; University of Kentucky Epilepsy Center (EpiC) (FG), Lexington; University of Melbourne (PK), Parkville, Australia; Centre Hospitalier Universitaire Vaudois (PR), Lausanne, Switzerland; Mayo Clinic (JS), Scottsdale, AZ; Spectrum Health Medical Group (BS), Grand Rapids, MI; MicroMass Communications, Inc. (AA), Cary, NC; and Verilogue, Inc. (LW), Horsham, PA.
Joseph SirvenDavid Geffen School of Medicine (JMS), University of California Los Angeles; University of Campinas (UNICAMP) and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) (FC), Campinas, São Paulo, Brazil; University of Kentucky Epilepsy Center (EpiC) (FG), Lexington; University of Melbourne (PK), Parkville, Australia; Centre Hospitalier Universitaire Vaudois (PR), Lausanne, Switzerland; Mayo Clinic (JS), Scottsdale, AZ; Spectrum Health Medical Group (BS), Grand Rapids, MI; MicroMass Communications, Inc. (AA), Cary, NC; and Verilogue, Inc. (LW), Horsham, PA.
Brien SmithDavid Geffen School of Medicine (JMS), University of California Los Angeles; University of Campinas (UNICAMP) and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) (FC), Campinas, São Paulo, Brazil; University of Kentucky Epilepsy Center (EpiC) (FG), Lexington; University of Melbourne (PK), Parkville, Australia; Centre Hospitalier Universitaire Vaudois (PR), Lausanne, Switzerland; Mayo Clinic (JS), Scottsdale, AZ; Spectrum Health Medical Group (BS), Grand Rapids, MI; MicroMass Communications, Inc. (AA), Cary, NC; and Verilogue, Inc. (LW), Horsham, PA.
Aleksandra AdomasDavid Geffen School of Medicine (JMS), University of California Los Angeles; University of Campinas (UNICAMP) and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) (FC), Campinas, São Paulo, Brazil; University of Kentucky Epilepsy Center (EpiC) (FG), Lexington; University of Melbourne (PK), Parkville, Australia; Centre Hospitalier Universitaire Vaudois (PR), Lausanne, Switzerland; Mayo Clinic (JS), Scottsdale, AZ; Spectrum Health Medical Group (BS), Grand Rapids, MI; MicroMass Communications, Inc. (AA), Cary, NC; and Verilogue, Inc. (LW), Horsham, PA.
Lauren WalterDavid Geffen School of Medicine (JMS), University of California Los Angeles; University of Campinas (UNICAMP) and the Brazilian Institute of Neuroscience and Neurotechnology (BRAINN) (FC), Campinas, São Paulo, Brazil; University of Kentucky Epilepsy Center (EpiC) (FG), Lexington; University of Melbourne (PK), Parkville, Australia; Centre Hospitalier Universitaire Vaudois (PR), Lausanne, Switzerland; Mayo Clinic (JS), Scottsdale, AZ; Spectrum Health Medical Group (BS), Grand Rapids, MI; MicroMass Communications, Inc. (AA), Cary, NC; and Verilogue, Inc. (LW), Horsham, PA.
Spectrum Health · USUniversity Hospital of Lausanne · CHUniversity of Kentucky · USMayo Clinic in Arizona · USUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEffective communication between patients and their health care providers is recognized as critically important to improve the quality of health services for individuals with epilepsy. We aimed to describe in-office neurologist-patient conversations about epilepsy and focus on disease identification, shared decision-making, and care planning.

methodsTranscripts and audio recordings of conversations between patients and neurologists in the United States, Spain, and Germany were analyzed linguistically in the topic areas of epilepsy identification and diagnosis, disease education, treatments, and care planning. Analyses included word-level assessments, topic switching, strategies of information elicitation, identification of topics discussed, quantification of questions asked, and assessment of types of questions asked.

resultsConversations of 17 neurologists in the United States, 12 in Spain, and 6 in Germany, with 50, 20, and 16 patients, respectively, were analyzed. Neurologists tended to utilize an event-based, patient-friendly vocabulary to refer to seizures, and in the United States, they avoided using the term "epilepsy." Regardless of who initiated the treatment discussion, the neurologists in all 3 countries were unilaterally responsible for the treatment decision and choice of medication. When describing a new medication, neurologists most often discussed potential side effects but did not review potential benefits. Neurologists rarely defined seizure control and did not ask patients what seizure control meant to them.

conclusionsWe identified opportunities related to vocabulary, decision-making, and treatment goal setting that could be targeted to improve neurologist-patient communication about epilepsy, and ultimately, the overall treatment experience and outcomes for patients.

Identifiers

PMID29708182
PMCPMC5914745
OpenAlexW2790229597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.